Annual report
7745.TEDINET S100TTWW
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 156
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥62.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥59.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥51.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥48.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥49.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥7.5bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥8.2bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.6bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.6bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.4bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥7.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥5.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥72.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥69.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥59.2bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥54.1bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥49.3bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.2bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥36.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥37.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥32.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥27.0bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥23.4bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥18.6bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥14.6bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥15.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥14.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥9.1bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥5.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥452m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥741m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥257m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥192.91 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.33 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.92 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥161.87 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥76.88 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥192.73 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥201.14 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥172.66 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥161.5 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.53 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,370.71 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,183.98 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,167.95 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,007.01 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥833.97 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.8% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.4% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 15.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 19.5% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,471 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 2,495 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 2,591 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 2,544 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 2,633 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.5bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥35.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥33.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥31.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥969m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥739m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥834m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.6bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥580m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.3bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥415m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥2.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥658m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥39.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥36.7bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥39.6bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥38.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥36.9bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥14.6bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥12.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥24.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥24.4bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥18.6bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥17.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥15.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.4bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥46.72 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.15 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥95.62 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.03 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.1 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥46.67 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥15.13 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥95.48 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥100.8 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.7 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥35 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥35 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥900.94 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥889.74 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥897.51 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥833.78 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥752.41 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 63.0% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.6% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.9% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 27,845,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 27,845,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,601,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,579,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,579,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 743 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 732 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 716 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 178
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥45m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥66m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥24.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥24.7bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | −¥10.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.8bn |
| America Measuring Instrumentsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥45m |
| America Measuring Instrumentsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥59m |
| America Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| America Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.2bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥595m |
| America Measuring Instrumentsreportable segment | segment assets | at 2024-03-31 | ¥4.1bn |
| America Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥158m |
| America Medical And Health Systemreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥5m |
| America Medical And Health Systemreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥58m |
| America Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥9.8bn |
| America Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.8bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| America Medical And Health Systemreportable segment | segment assets | at 2024-03-31 | ¥5.2bn |
| America Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥609m |
| Asia And Oceania Measuring Instrumentsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥144m |
| Asia And Oceania Measuring Instrumentsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥146m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥7.5bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment assets | at 2024-03-31 | ¥7.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥260m |
| Asia And Oceania Medical And Health Systemreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥94m |
| Asia And Oceania Medical And Health Systemreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥225m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥8.2bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥377m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥7.8bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment assets | at 2024-03-31 | ¥4.2bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥335m |
| Europe Measuring Instrumentsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2m |
| Europe Measuring Instrumentsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥9m |
| Europe Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥601m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥601m |
| Europe Measuring Instrumentsreportable segment | segment assets | at 2024-03-31 | ¥422m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥104m |
| Europe Medical And Health Systemreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥64m |
| Europe Medical And Health Systemreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥93m |
| Europe Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥8.0bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥8.0bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥16m |
| Europe Medical And Health Systemreportable segment | segment assets | at 2024-03-31 | ¥7.5bn |
| Europe Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥425m |
| Japan Measuring Instrumentsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥520m |
| Japan Measuring Instrumentsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥714m |
| Japan Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥20.9bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥18.3bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Japan Measuring Instrumentsreportable segment | segment assets | at 2024-03-31 | ¥31.0bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Japan Medical And Health Systemreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥456m |
| Japan Medical And Health Systemreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥180m |
| Japan Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥16.5bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥11.1bn |
| Japan Medical And Health Systemreportable segment | segment assets | at 2024-03-31 | ¥9.5bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.9bn |
| Japan Semiconductor Related Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Japan Semiconductor Related Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥194m |
| Japan Semiconductor Related Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.3bn |
| Japan Semiconductor Related Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.3bn |
| Japan Semiconductor Related Businessreportable segment | segment assets | at 2024-03-31 | ¥12.9bn |
| Japan Semiconductor Related Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Measurement Weighing Instruments Businessesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥712m |
| Measurement Weighing Instruments Businessesreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥929m |
| Measurement Weighing Instruments Businessesreportable segment | employees | at 2024-03-31 | 1106 pure |
| Measurement Weighing Instruments Businessesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥33.8bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥28.1bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.8bn |
| Measurement Weighing Instruments Businessesreportable segment | segment assets | at 2024-03-31 | ¥43.2bn |
| Measurement Weighing Instruments Businessesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.8bn |
| Medical Healthcare Instruments Businessesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥621m |
| Medical Healthcare Instruments Businessesreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥556m |
| Medical Healthcare Instruments Businessesreportable segment | employees | at 2024-03-31 | 1190 pure |
| Medical Healthcare Instruments Businessesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥42.5bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥23.6bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥18.9bn |
| Medical Healthcare Instruments Businessesreportable segment | segment assets | at 2024-03-31 | ¥26.3bn |
| Medical Healthcare Instruments Businessesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥4.2bn |
| Semiconductor Related Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Semiconductor Related Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥194m |
| Semiconductor Related Businessreportable segment | employees | at 2024-03-31 | 123 pure |
| Semiconductor Related Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.3bn |
| Semiconductor Related Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.3bn |
| Semiconductor Related Businessreportable segment | segment assets | at 2024-03-31 | ¥12.9bn |
| Semiconductor Related Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥77m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥62m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥27.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥27.6bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥9.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥2.1bn |
| America Measuring Instrumentsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥201m |
| America Measuring Instrumentsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥52m |
| America Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.0bn |
| America Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥5.5bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥468m |
| America Measuring Instrumentsreportable segment | segment assets | at 2023-03-31 | ¥3.8bn |
| America Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥702m |
| America Medical And Health Systemreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥156m |
| America Medical And Health Systemreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥57m |
| America Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9.3bn |
| America Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥9.3bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥3m |
| America Medical And Health Systemreportable segment | segment assets | at 2023-03-31 | ¥4.9bn |
| America Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥139m |
| Asia And Oceania Measuring Instrumentsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥187m |
| Asia And Oceania Measuring Instrumentsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥145m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥8.1bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥4.8bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥3.3bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment assets | at 2023-03-31 | ¥7.0bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥503m |
| Asia And Oceania Medical And Health Systemreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥455m |
| Asia And Oceania Medical And Health Systemreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥200m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9.1bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥405m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥8.7bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment assets | at 2023-03-31 | ¥4.0bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥253m |
| Europe Measuring Instrumentsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥18m |
| Europe Measuring Instrumentsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥13m |
| Europe Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥905m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥904m |
| Europe Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥0 |
| Europe Measuring Instrumentsreportable segment | segment assets | at 2023-03-31 | ¥622m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥101m |
| Europe Medical And Health Systemreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥324m |
| Europe Medical And Health Systemreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥86m |
| Europe Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9.4bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥9.4bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥5m |
| Europe Medical And Health Systemreportable segment | segment assets | at 2023-03-31 | ¥6.8bn |
| Europe Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Japan Measuring Instrumentsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥883m |
| Japan Measuring Instrumentsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥767m |
| Japan Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥19.8bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥16.3bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥3.5bn |
| Japan Measuring Instrumentsreportable segment | segment assets | at 2023-03-31 | ¥32.2bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.2bn |
| Japan Medical And Health Systemreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥255m |
| Japan Medical And Health Systemreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥163m |
| Japan Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥17.1bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥5.4bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥11.6bn |
| Japan Medical And Health Systemreportable segment | segment assets | at 2023-03-31 | ¥7.9bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.9bn |
| Japan Semiconductor Related Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥130m |
| Japan Semiconductor Related Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥151m |
| Japan Semiconductor Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.9bn |
| Japan Semiconductor Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥6.9bn |
| Japan Semiconductor Related Businessreportable segment | segment assets | at 2023-03-31 | ¥11.7bn |
| Japan Semiconductor Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Measurement Weighing Instruments Businessesreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Measurement Weighing Instruments Businessesreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥978m |
| Measurement Weighing Instruments Businessesreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥34.9bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥27.6bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.3bn |
| Measurement Weighing Instruments Businessesreportable segment | segment assets | at 2023-03-31 | ¥43.6bn |
| Measurement Weighing Instruments Businessesreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Medical Healthcare Instruments Businessesreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥1.2bn |
| Medical Healthcare Instruments Businessesreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥508m |
| Medical Healthcare Instruments Businessesreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥44.8bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥24.5bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥20.3bn |
| Medical Healthcare Instruments Businessesreportable segment | segment assets | at 2023-03-31 | ¥23.6bn |
| Medical Healthcare Instruments Businessesreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥4.7bn |
| Semiconductor Related Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥130m |
| Semiconductor Related Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥151m |
| Semiconductor Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.9bn |
| Semiconductor Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥6.9bn |
| Semiconductor Related Businessreportable segment | segment assets | at 2023-03-31 | ¥11.7bn |
| Semiconductor Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,901
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | － | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.866 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.689 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.360 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 2.004 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 3.984 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.905 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.286 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.312 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.388 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.962 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02344-000SemiconductorRelatedBusinessReportableSegmentMember | 123 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02344-000SemiconductorRelatedBusinessReportableSegmentMember | 28 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 1190 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 94 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02344-000MeasurementWeighingInstrumentsBusinessesReportableSegmentsMember | 1106 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02344-000MeasurementWeighingInstrumentsBusinessesReportableSegmentsMember | 207 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 52 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 12 | |
| Number of employees | CurrentYearInstant | 2471 | |
| Average number of temporary workers | CurrentYearInstant | 341 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | － | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | － | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | － | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | － | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | － | JPY |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.005 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.737 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.460 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.668 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.390 | |
| Research and development expenses research and development activities | CurrentYearDuration | 5101000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02344-000SemiconductorRelatedBusinessReportableSegmentMember | 783000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 1074000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02344-000MeasurementWeighingInstrumentsBusinessesReportableSegmentsMember | 3243000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 1878000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02344-000SemiconductorRelatedBusinessReportableSegmentMember | 958000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 461000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02344-000MeasuringInstrumentsReportableSegmentsMember | 449000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 27845208 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 27845208 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 27845208 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 27845208 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 23 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 24 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 77 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 131 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 21 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |